ReviewAdvances in therapy2022

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.

Dominic Brittain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.